05:51 PM EDT, 05/21/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said Tuesday it has aligned with Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica at their Joint Strategy Committee to transfer the global sponsorship of the phase 3 head and neck cancer trial of NBTXR3 in preparation for potential regulatory submission in the event of positive trial results.

The firm said it will continue to support Janssen in execution of NANORAY-312, a phase 3 study evaluating the radioenhancer for elderly patients with locally advanced head and neck cancer, during and after the sponsorship transfer is complete.

Nanobiotix ( NBTX ) also said it is vetting options for extension of its cash runway beyond the current expectation of Q3 2025.

Price: 7.10, Change: -0.01, Percent Change: -0.14